Peptides for Healing: What Is Actually Prescribed, How Each One Works, and What It Costs

The first hours after injury are dominated by clotting, then by neutrophils and macrophages clearing damaged tissue and releasing the signals that recruit repair cells. Nothing rebuilds until that has happened. The problem is inflammation that never hands off to the next phase: a joint still warm at week eight, or a tendon that flares every time it is loaded, describes a signaling loop that has not resolved. That is the phase KPV is aimed at, and why KPV sits in KLOW.

Fibroblasts, the cells that manufacture collagen, migrate into a wound along the fibrin scaffold, and migration depends on the cell rearranging its internal actin skeleton to crawl. This is the step TB-500 is described as acting on: thymosin beta-4, the parent protein, binds actin. A repair with no cellular workforce inside it stays a defect however long it is rested.

Tendon and ligament are among the least vascular tissues in the body, so the oxygen and nutrient delivery every other phase depends on is limited from the start. This is why a mid-substance tendon injury takes months where a skin cut takes days, and why angiogenesis is the mechanism described most often for BPC-157 and part of the literature on GHK-Cu.

Fibroblasts first secrete thin, disorganized type III collagen; over weeks to months it is replaced by load-bearing type I collagen, with fibers aligning along the direction of stress. Alignment only happens under load: tissue that is never stressed remodels into scar. This is the phase where GHK-Cu is described, through copper-dependent enzymes involved in collagen cross-linking, and the phase no injection substitutes for, because the mechanical signal comes from rehabilitation. Most chronic tendinopathy is now understood as failed healing rather than ongoing inflammation.

A 15-amino-acid fragment of a protein found in gastric juice, with the largest animal literature in this category. The mechanism described most consistently is angiogenesis: a 2017 paper in the Journal of Molecular Medicine reported BPC-157 activating the VEGFR2 receptor in cell and animal models. A 2014 paper in Molecules reported increased growth hormone receptor expression in cultured tendon fibroblasts, which makes those cells more responsive to growth hormone already circulating; it does not raise growth hormone.

The orthopedic animal work is why it is prescribed for injury. The Journal of Orthopaedic Research published rat studies on transected Achilles tendon (2003), Achilles detachment (2006), transected quadriceps muscle (2006) and medial collateral ligament transection (2010), each reporting functional, biomechanical and histological improvement in treated animals. A 2019 review in Cell and Tissue Research summarized this literature as consistently positive in animals while stating that efficacy in humans is yet to be confirmed.

Human data is thin. A 2021 retrospective chart review in Alternative Therapies in Health and Medicine described 17 patients given intra-articular BPC-157 for knee pain, most reporting relief by telephone survey: small, uncontrolled, and without standardized outcome measures. There are no randomized controlled trials of BPC-157 for tendon, ligament or muscle injury in humans.

BPC-157 alone tends to suit gut-lining complaints, where the original research sits, and injuries where blood supply is the obvious limit. For soft-tissue injury it is more often prescribed with TB-500. Full reference: what is BPC-157.

A synthetic fragment corresponding to the active region of thymosin beta-4, one of the most abundant proteins inside human cells. Its central function is binding actin, which is why the research is organized around cell migration. A 1997 paper in the FASEB Journal reported thymosin beta-4 stimulating directional migration of human endothelial cells, a 1999 paper in the Journal of Investigative Dermatology described faster dermal wound closure in animals, and a 2003 paper in Wound Repair and Regeneration reported the same in diabetic and aged mice using a short peptide containing the actin-binding domain, the region TB-500 reproduces.

TB-500 is distinctive here for having randomized human data on the parent molecule. A 2010 study in the Annals of the New York Academy of Sciences gave intravenous synthetic thymosin beta-4 to healthy volunteers against placebo and reported no dose-limiting toxicity. A 2012 paper in the same journal summarized two phase 2 trials in pressure and venous stasis ulcers, and a 2015 phase 2 randomized trial in Cornea reported improvement in severe dry eye. None is a tendon trial and none used the fragment as compounded; they establish that the parent protein has been given to people under controlled conditions, not that TB-500 repairs tendons.

A 2026 rat study in Joint Diseases and Related Surgery compared BPC-157, TB-500 and the two together after Achilles injury and reported higher load-to-failure with TB-500 and improved histology with both, with no additional benefit from the combination. It is a single preliminary study, but the first head-to-head comparison.

TB-500 tends to suit injuries where nothing is rebuilding: a repair that has stalled rather than one that is inflamed. See what is TB-500.

A naturally occurring copper-binding tripeptide first described in a 1973 paper in Nature New Biology, found in human plasma at concentrations that decline with age. It delivers copper to the enzymes that need it, including lysyl oxidase, which cross-links collagen. A 1988 paper in FEBS Letters reported stimulation of collagen synthesis in cultured fibroblasts and a 1993 paper in the Journal of Clinical Investigation reported connective tissue accumulation in vivo; a 1999 paper in the Journal of Investigative Dermatology described effects on the matrix metalloproteinases that break tissue down. A 2015 review in BioMed Research International covers the gene-expression work that followed.

GHK-Cu has the deepest human record of the four, though almost entirely topical. A 1994 multicenter blinded placebo-controlled trial in Wound Repair and Regeneration tested a topical GHK-Cu gel on diabetic foot ulcers alongside standard wound care and reported a median area reduction of 98.5 percent versus 60.8 percent with vehicle, with fewer infections. There are no randomized trials of injectable GHK-Cu for musculoskeletal injury; that use rests on mechanism and prescriber experience.

GHK-Cu is the component doing visible work if skin quality, scarring or collagen is part of the goal, and the reason GLOW and KLOW exist as distinct products. See what is GHK-Cu.

The last three amino acids of alpha-melanocyte-stimulating hormone, carrying the anti-inflammatory signaling of the parent hormone without its pigmentation effect. A 2008 paper in Gastroenterology reported KPV entering intestinal cells through the PepT1 transporter and reducing NF-kB and MAPK activation and the cytokines downstream, with reduced inflammation in mouse colitis models; a 2008 paper in Inflammatory Bowel Diseases and a 2017 paper in Molecular Therapy reported the same in murine IBD models. There are no randomized human trials of KPV for any indication; a physician prescribing it is doing so on mechanism.

KPV tends to suit problems where inflammation is the phase that will not resolve: a joint or tendon that stays reactive, or a gut complaint with an inflammatory character. On its own it is not a repair peptide; in KLOW it addresses the first row of the phase table so the other three can address the rest. See what is KPV.

The usual prescription for a tendon, ligament or muscle injury, because the two are described as acting on different phases: BPC-157 on blood supply and fibroblast responsiveness, TB-500 on cell migration and matrix organization, supplied in one vial. The evidence for the pair is the sum of the evidence for each, plus the 2026 rat comparison, in which the combination did not add to TB-500 alone. Whether that translates to humans is unknown, and a physician may reasonably prescribe either alone. Directions and pricing are on the BPC-157 + TB-500 page.

GLOW is GHK-Cu, BPC-157 and TB-500 in one vial: the prescription when injury is the reason for the consultation but skin, scarring or tissue quality is part of the goal. KLOW is GLOW plus KPV and maps onto every row of the phase table; it tends to be chosen when an injury has been slow for months and remains reactive to load. Neither is a stronger version of the others; KLOW is a wider one.

This is the strongest area for BPC-157 and it is entirely preclinical. The rat studies of 2003 through 2010 report faster functional recovery, better biomechanical properties and better histology in treated animals, measured by time to weight-bearing and force at failure rather than subjective reports; the 2018 review in Current Pharmaceutical Design collects them. For TB-500 the tendon-specific data is thinner and newer; most thymosin beta-4 work is in skin, cornea and heart. A 2026 review in Sports Medicine surveying approved and unapproved peptides in musculoskeletal injury summarized the position accurately: favorable tissue-repair outcomes in animal models, scarce rigorous human safety and efficacy data.

Skin is where this category has real human trials, because skin is easy to measure. The GHK-Cu diabetic ulcer trial of 1994 was blinded and placebo-controlled. Thymosin beta-4 has phase 2 ulcer trials and a phase 2 dry-eye trial. LL-37, a component of FORTIFY, has two randomized placebo-controlled trials in hard-to-heal venous leg ulcers, in Wound Repair and Regeneration in 2014 and 2021. All are topical or ophthalmic and none is a subcutaneous injection for a tendon, so they support the biology of the molecules rather than the specific use a healing patient is asking about. BPC-157's own largest literature is the gut, summarized in a 2011 review in Current Pharmaceutical Design.

There are no randomized controlled trials of BPC-157, TB-500, GHK-Cu or KPV as injectable treatments for tendon, ligament or muscle injury in humans. The human record is the thymosin beta-4 trials on the parent protein, the topical GHK-Cu wound trials, the 17-patient BPC-157 knee chart review, and prescriber experience. A provider who tells you these are proven to repair tendons in people is overstating it; one who tells you there is no evidence at all is understating it.

• An effect size in humans, because that trial has not been run.
• A human timeline. The windows later on this page are prescriber experience, not endpoints.
• Superiority of a blend over a single peptide in people. The only head-to-head is one rat study, and it did not favor the combination.
• Long-term safety over years of continuous use, which is why physician review continues.
• Efficacy for any condition as an approved treatment. None of the four is FDA approved for anything.

From 2023 until April 2026, BPC-157, TB-500, KPV and injectable GHK-Cu all sat in Category 2 of the FDA's interim 503A bulk drug substances list, the category for nominated substances flagged as raising significant safety risks. On 15 April 2026 the FDA announced it was removing twelve peptides from Category 2 because the nominations behind them had been withdrawn, effective about a week later, and all four were among them. The FDA's safety-risk page, current as of 22 April 2026, now lists BPC-157, TB-500, GHK-Cu and KPV under substances nominated but withdrawn rather than in Category 2. The current published category list, updated 14 May 2026, names none of the four in Category 2.

Removal lifts the safety-risk designation. It does not by itself place a substance on the positive 503A Bulks List; the FDA was explicit that removal does not establish that a substance meets the criteria for compounding.

The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and took up BPC-157 (reviewed for ulcerative colitis), KPV (wound healing and inflammatory conditions) and TB-500 (wound healing) on the first day, each as the free base and the acetate. The FDA's briefing document noted that each nomination had been withdrawn, stated that the agency was "electing to proceed" regardless, and proposed that none of the three be included, for either salt form. The committee voted the other way: 8 to 6 with one abstention to recommend adding BPC-157, and by the same margin to recommend adding KPV and TB-500, to the 503A Bulks List. The committee recommended six of the seven peptides on its agenda.

A committee vote is a recommendation, not a decision. The FDA issues its own determination after weighing the vote, public comment and its scientific review, and adding a substance to the Bulks List requires rulemaking. As of September 2026 that determination is pending for all three.

GHK-Cu was not on the July agenda; the FDA has said it intends to consult the committee on it before the end of February 2027. One wrinkle: after the April withdrawal, one nominator clarified on 5 May 2026 that it meant to withdraw only the injectable route, and on 14 May 2026 the FDA added "GHK-Cu (except for injectable routes of administration)" back to Category 1, the list of substances under evaluation. Injectable GHK-Cu, the form in GLOW, KLOW and the GHK-Cu product, is therefore where BPC-157 and TB-500 were between April and July: no longer flagged, not yet reviewed for the positive list.

None of the four is an FDA-approved drug product, and compounded medications never are. They are prepared by a state-licensed pharmacy to an individual physician's prescription rather than approved as manufactured products, and it is legal to prescribe and dispense them with a valid prescription. What changed in 2026 is that the safety-risk flag was lifted and three of the four have a formal recommendation for the positive list; none is approved for any indication.

The WADA Prohibited List in force is the 2026 list, effective 1 January 2026. USADA states that BPC-157 is prohibited at all times under section S0, non-approved substances, which covers any pharmacological substance with no current approval for human therapeutic use. TB-500 is a fragment of thymosin beta-4, a growth factor, and growth factors and their modulators are prohibited at all times under section S2. KPV and injectable GHK-Cu fall under the same S0 logic. A tested athlete should check Global DRO or their anti-doping organization before starting anything on this page, and say so on the intake.

A complete tendon rupture, a displaced fracture, a full-thickness rotator cuff tear or a bucket-handle meniscal tear is a surgical question. No peptide bridges a gap that has to be closed mechanically, and a physician who suspects one will ask for imaging before prescribing.

An inflamed tendon in someone who keeps doing the thing that inflamed it will keep being inflamed. Training load, technique, footwear and workstation come up on a good intake because a peptide cannot outrun a cause that reintroduces the problem daily; the same applies to a gut lining being re-injured by a medication or alcohol. Worsening rather than plateaued pain, night pain, numbness, weakness, a joint that locks or gives way, fever, or unexplained swelling are reasons to investigate before treating.

Most of what is reported early is not tissue changing but background inflammation settling, and some people notice nothing at all in this window, which is normal. Injection-site redness or tenderness is the commonest report.

This is where tissue-level change would be expected if it occurs, based on the animal timelines, and why a vial is sized around 28-day refills. The clearest sign patients describe is not the absence of pain at rest but better tolerance of loading: the tendon that used to flare the day after rehabilitation no longer does. That is what a physiotherapist and a physician both look for.

A recent acute injury is generally described as responding faster than a problem present for a year, because the chronic case has usually remodeled into scar and has to be reorganized under load rather than simply repaired. Chronic problems are where KLOW and GLOW are more often chosen, and where expectations belong at months rather than weeks. Because there are no trial endpoints, "working" has to be defined in advance with your physician: a specific load, a distance, a movement, a morning stiffness duration. Treatment is long-term with 28-day refills, and if the agreed marker has not moved, the physician may change the prescription.